A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents

A pharmacodynamic model is proposed and equations are developed for the quantitative analysis of dose-time-cell-survival curves produced by the administration of cell-cycle-specific chemo-therapeutic agents. The essential feature of the model is an irreversible, bimolecular mechanism of drug-receptor interaction which serves as the interface between the pharmacokinetics of the drug and the cell-cycle-cell-proliferation kinetics of the normal and neoplastic cells. A preliminary cell system which allows adequate characterization of the experimental data is a two-compartment model where cells are assumed to exist in their proliferative and nonproliferative phases. The chemotherapeutic model was used to analyze dose-time-cell-survival curves found in the literature for the effects of vincristine, vinblastine, arabinosylcytosine, and cyclophosphamide on lymphoma and hematopoietic cells in the mouse femur. Similarity in the values of the “cell-kill” constants for these drugs on the two cell types indicates that, in the cell systems studied, the proliferative state of the cells is the primary in vivodeterminant of selective chemotherapy.

[1]  R. Dedrick,et al.  In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosine. , 1972, Biochemical pharmacology.

[2]  W. R. Bruce,et al.  An in vitro assay for growth-inhibiting activity of vinblastine. , 1965, Journal of the National Cancer Institute.

[3]  Kenneth B. Bischoff,et al.  Mathematical representations of cancer chemotherapy effects , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  W. C. Werkheiser,et al.  MATHEMATICAL SIMULATION IN CHEMOTHERAPY * , 1971, Annals of the New York Academy of Sciences.

[5]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[6]  W. R. Bruce,et al.  Comparison of the sensitivity of hematopoietic colony-forming cells in different proliferative states to vinblastine. , 1967, Journal of the National Cancer Institute.

[7]  G. Hahn A formalism describing the kinetics of some mammalian cell populations , 1970 .

[8]  S. I. Rubinow,et al.  Parameterization of in vivo leukemic cell populations. , 1971, Biophysical Journal.

[9]  C A Bingham,et al.  The cell cycle and cancer chemotherapy. , 1978, The American journal of nursing.

[10]  H. H. Lloyd,et al.  Kinetic parameters and growth curves for experimental tumor systems. , 1970, Cancer chemotherapy reports.

[11]  W. R. Bruce,et al.  Comparison of the dose- and timesurvival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine, and amethopterin. , 1969, Journal of the National Cancer Institute.

[12]  M. Randall,et al.  Formulation and computation of compartment models. , 1970, Journal of pharmaceutical sciences.

[13]  R. Moran,et al.  Mathematical simulation of the interaction of drugs that inhibit deoxyribonucleic acid biosynthesis. , 1973, Molecular pharmacology.

[14]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[15]  K. Bischoff,et al.  Models of ARA-C chemotherapy of L1210 leukemia in mice , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  K. Bischoff,et al.  Pharmacokinetics and Cell Population Growth Models in Cancer Chemotherapy , 1973 .

[17]  B. Meeker,et al.  DISSEMINATION AND GROWTH OF TRANSPLANTED ISOLOGOUS MURINE LYMPHOMA CELLS. , 1964, Journal of the National Cancer Institute.

[18]  W. Jusko Pharmacokinetic principles in pediatric pharmacology. , 1972, Pediatric clinics of North America.